S 832

0likesShare

Introduced ↻ Update bill dataRe-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click. Contact your reps Urge the sponsor

IN THE SENATE OF THE UNITED STATES

March 4, 2025

Mr. Tillis (for himself, Mr. Budd, Mrs. Blackburn, Mr. Daines, and Mr. Lankford) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Ensuring Pathways to Innovative Cures Act of 2025” or the “EPIC Act of 2025”.

SEC. 2. EQUALIZING THE NEGOTIATION PERIOD BETWEEN SMALL-MOLECULE AND BIOLOGIC CANDIDATES UNDER THE DRUG PRICE NEGOTIATION PROGRAM.

Section 1192(e)(1)(A)(ii) of the Social Security Act (42 U.S.C. 1320f-1(e)(1)(A)(ii)) is amended—

(1) by striking “year, at least 7” and inserting “year—

“(I) for initial price applicability years 2026 and 2027, at least 7”; and

(2) by adding at the end the following:

“(II) for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and”. <all>